Enzyme News and Research

RSS

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

29 Jul 2010

Two middle school students join scientists to research on key bacterial enzyme

Grown-ups aren't the only ones making exciting scientific discoveries these days. Two middle school students from Wisconsin joined a team of scientists who are reporting the first glimpse of the innermost structure of a key bacterial enzyme. It helps activate certain antibiotics and anti-cancer agents so that those substances do their job. Their study appears in ACS' weekly journal Biochemistry.

29 Jul 2010

Advanced Protein Systems is now APS BioGroup

APS BioGroup, formerly Advanced Protein Systems, the world's largest producer of colostrum products, announces its new company name and expanded focus to include advancements in private label contract manufacturing for health supplements and the introduction of Immulox®, an immune support product and supplement ingredient derived from colostrum.

29 Jul 2010

Researchers unveil mechanism of cholera bacteria to create cell energy

Researchers have found that an enzyme in the bacteria that causes cholera uses a previously unknown mechanism in providing the bacteria with energy. Because the enzyme is not found in most other organisms, including humans, the finding offers insights into how drugs might be created to kill the bacteria without harming humans.

29 Jul 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

New implantable sensor to continuously monitor tissue glucose

Bioengineers at the University of California, San Diego and GlySens Incorporated have developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. The paper, published in the July 28, 2010 issue of the journal Science Translational Medicine, describes the use of this glucose-sensing device as an implant in animals for over one year. After human clinical trials and FDA approval, the device may be useful to people with diabetes as an alternative to finger sticking and short-term, needle-like glucose sensors that have to be replaced every three to seven days.

29 Jul 2010

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

A new study reveals that an enzyme linked with multiple disorders is also involved in the generation of toxic, neuron-killing protein fragments in Huntington's disease (HD). The research, published by Cell Press in the July 29 issue of Neuron, provides insight into Huntington's pathology and proposes new therapeutic strategies for this devastating incurable disease.

29 Jul 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

Scientists develop novel chemotherapeutic method for anticancer drug delivery

Combining nature and Greek mythology, researchers at the Technion-Israel Institute of Technology have developed a tiny "Trojan Horse" system for delivering cancer-fighting drugs. With this system, the drugs are delivered only once they are inside the cancerous cells, so there is no damage to the healthy cells in the surrounding area.

28 Jul 2010

Process improvement program improves adherence to evidence-based CRT, ICD and drug therapy

Results of the largest U.S. outpatient heart failure clinical study show that implementation of a process improvement program significantly improved adherence to evidence-based, guideline-recommended cardiac resynchronization therapy (CRT), implantable cardioverter-defibrillator (ICD) and drug therapy.

27 Jul 2010

Study tests new performance intervention to improve heart failure patients in outpatient setting

A study led by UCLA tested a new performance intervention to help improve adherence to national guideline-recommended therapies for heart failure patients in an outpatient setting.

27 Jul 2010

Researchers discover potential method for neurodegenerative disease detection

New investigations, initiated by research workers at CIC bioGUNE and led by Dr. Aitor Hierro, have opened possibilities for making progress in the knowledge and prediction of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), according to the journal of The Proceedings of the National Academy of Sciences of the United States of America.This study opens the possibility of research in humans to detect this pathology before the symptoms arise.

26 Jul 2010

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Scientists at Washington University School of Medicine in St. Louis have found a way to significantly reduce atherosclerosis in mice that does not involve lowering cholesterol levels or eliminating other obesity-related problems.

26 Jul 2010

Scientists discover repair mechanism of photolyase in sun damaged DNA

Researchers have long known that humans lack a key enzyme one possessed by most of the animal kingdom and even plants that reverses severe sun damage.For the first time, researchers have witnessed how this enzyme works at the atomic level to repair sun-damaged DNA.The discovery holds promise for future sunburn remedies and skin cancer prevention.

26 Jul 2010

Drugs that activate SIRT1 hold potential to combat Alzheimer's: Study

MIT biologists report that they have discovered the first link between the amyloid plaques that form in the brains of Alzheimer's patients and a gene previously implicated in the aging process, SIRT1.

23 Jul 2010

Study reveals link between anti-TPO antibodies and placental abruption

Pregnant women with antibodies that can indicate early thyroid disease are three times as likely to have placental separation during labor, researchers at UT Southwestern Medical Center have found in a study of more than 17,000 women.

22 Jul 2010

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

Survey links autism with digestive problems, intestinal inflammation

Autism is the fastest growing developmental disorder in the world. With 1 child in 91 facing the disorder, the diagnosis is more common than pediatric cancer, diabetes, and AIDS combined.

22 Jul 2010

Researchers block central pathway for prostate cancer progression

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

21 Jul 2010